Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.41 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | SI | P14410 | 3/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770188 | 0.93 | ESR2 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5768982 | 0.88 | ALDH2 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5946257 | 0.87 | MAPT (0.47) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL5772174 | 0.86 | SLC6A3 (0.53) | ALDH1A1 | |
| SCHEMBL6370434 | 0.79 | HTR3A (0.47) | — | |
| SCHEMBL6377962 | 0.79 | HTR3A (0.47) | — | |
| SCHEMBL28680034 | 0.78 | PTGS2 (0.46) | HTTALDH1A1POLBKMT2A | |
| SCHEMBL5768977 | 0.77 | PRMT3 (0.38) | HTTGAAALDH1A1POLBKMT2A | |
| SCHEMBL16112588 | 0.74 | HTT (0.52) | HTTALDH1A1KMT2ASGK1CAMKK2 | |
| SCHEMBL3493408 | 0.74 | HTT (0.46) | HTTGAAALDH1A1KMT2ASGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138496-A1 | Antitumoral analogs of lamellarins | Pharma Mar, S.A.U. (ES) | 2009-12-30 | — | — | EP | disclosed |
| US-7396837-B2 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2008-07-08 | — | — | US | disclosed |
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2006-12-21 | — | — | US | disclosed |
| EP-1613635-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004073598-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A.U. (ES) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | TSNAX, TSN, PLIN5 | CA12 3084/4885CA1 2605/4885CA2 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.